Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range

References

• Lip GY, Kakar P, Watson T. Atrial fibrillation – the growing epidemic. Heart 2007;93:542–3
   Google Scholar
• Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286–92
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians; 2006
   Google Scholar
• Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines [Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation] developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651–745
   PubMed Web of Science ®Google Scholar
• Taggar JS, Lip GY. Anticoagulation for elderly patients with atrial fibrillation: not to be neglected. Europace 2008;10:1–2
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Capucci A, Lip GY, et al.; HJ; Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27:3018–26
   Google Scholar
• Fang MC, Go AS, Chang Y, et al.; ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008;51:810–5
   Google Scholar
• Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999;131:927–34
   PubMed Web of Science ®Google Scholar
• Hylek EM, D’Antonio J, Evans-Molina C, et al. Translating the results of randomised trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006;37:1075–80
   PubMed Web of Science ®Google Scholar
• Lane D, Lip GY. Anti-thrombotic therapy for atrial fibrillation and patients’ preferences for treatment. Age Ageing 2005;34:1–3
   PubMed Web of Science ®Google Scholar
• Lip GYH, Kamath S, Jafri M, et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. Stroke 2002;33:238–42
   PubMed Web of Science ®Google Scholar
• Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002;36:200–4
   PubMed Web of Science ®Google Scholar
• Derevereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation. Br Med J 2001;323:1–7
   PubMedGoogle Scholar
• Lip GY, Zarifis J, Watson RD, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart 1996;75:200–5
   PubMed Web of Science ®Google Scholar
• Fang M, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med 2007;120:481–7
   Google Scholar
• Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503
   PubMed Web of Science ®Google Scholar
• Hughes M, Lip GY; Guideline Development Group for the NICE National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007;100:599–607
   Google Scholar
• Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689–96
   PubMed Web of Science ®Google Scholar
• Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis 2008;25:26–32
   PubMed Web of Science ®Google Scholar
• Lip GY. Don’t add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. Br Med J 2008;336:614–5
   PubMed Web of Science ®Google Scholar
• Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823–7
   PubMed Web of Science ®Google Scholar
• Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New Engl J Med 2003;349:1019–26
   PubMed Web of Science ®Google Scholar
• Lane DA, Boos CJ, Lip GY. Anticoagulation control with vitamin K antagonists: how well are we doing? Chest 2006;129:1122–4
   Google Scholar
• Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691–8
   Google Scholar
• ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–12
   Google Scholar
• Dolan G, Smith LA, Collins S, Plumb JM. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta analysis of the literature. Curr Med Res Opin 2008;24(5):1459–72
   PubMed Web of Science ®Google Scholar
• van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155–66
   PubMed Web of Science ®Google Scholar